Key Highlights

  • 48% is the decline for Fractyl Health (NASDAQ:GUTS), to USD 2.17 against the October 15 close of USD 4.16 per published market data (October 16, 2026 premarket), own arithmetic. It followed a company release the same day showing the REMAIN-1 cohort met a co-primary endpoint.
  • 40% is the decline for MDxHealth (NASDAQ:MDXH), to USD 0.3601 against a USD 0.6036 close. On October 15, 2026 it reported preliminary third quarter revenue of USD 22.7 million, 7.5% below consensus of USD 24.55 million, and suspended USD 110 million to USD 115 million guidance.
  • 21% is the decline for Curis (NASDAQ:CRIS), to USD 0.4022 from an implied USD 0.508, with no company-specific catalyst identified through October 16, 2026. Cash was USD 5.1 million at June 30, against a six-month net loss of USD 32.8 million and going-concern doubt.
  • 20.48% is the decline for Jaguar Health (NASDAQ:JAGX), to USD 3.65 on October 16, 2026, the ex-dividend date of a Series R preferred dividend that converts into five common shares on November 2. The company has not linked the two, so the cause is not confirmed.

Fractyl Health (NASDAQ:GUTS)

On October 16, 2026, Fractyl reported six-month data from REMAIN-1, a randomized, sham-controlled study of 308 adults who first lost at least 15% of body weight on tirzepatide. Revita patients regained a mean 5.1% versus 8.2% for sham, with a p-value of 0.0023, per the company release. Neither the release nor the 8-K states a cause for the fall, so any reason is interpretation. The 3.1 percentage point gap is modest, the 3.8% regain in ablations of 20 centimeters or more is a post hoc subgroup, and the second co-primary endpoint, a 12-month hurdle, reads out in the first quarter of 2027. Volume was 8.52 million shares, USD 18.5 million of turnover or 33.5% of market capitalization, own arithmetic. Cash fell 42% to USD 47.1 million between December 31 and June 30, with substantial doubt regarding going concern. At USD 6.4 million a month of operating cash use, runway is 7.4 months, own arithmetic. A 1-for-12 reverse split took effect on October 2. Fractyl Health (NASDAQ:GUTS) has announced no raise, yet each share or warrant sold to fund the De Novo filing dilutes holders, and a class action lead plaintiff deadline falls on October 20.

MDxHealth (NASDAQ:MDXH)

MDxHealth reported preliminary third quarter revenue from continuing operations of USD 22.7 million, flat on a year earlier and 7.5% below the published consensus of USD 24.55 million, own arithmetic. It suspended 2026 revenue guidance, and the chief executive tied the shortfall to unexpected sales force turnover. A diagnostics business earns revenue when physicians order tests, so lost representatives cut volume until territories are refilled. Tissue-based test volume fell 11% to 11,232, while the Exo mdx urine test rose to 11,792 from 4,600. Turnover was USD 351,000, 1.0% of the USD 34.36 million market capitalization, own arithmetic. Cash was USD 31.7 million at September 30, 2026. Non-current loans were USD 96.4 million at June 30, total equity was negative USD 30.4 million, and covenant compliance is a listed risk. Lake Street and Craig-Hallum moved to Hold on October 16. A Nasdaq minimum bid notice dated July 2 carries a 180-day cure period ending December 29, 2026, own arithmetic. MDxHealth (NASDAQ:MDXH) reports in full on November 12, 2026.

Curis (NASDAQ:CRIS)

No company-specific news explains the slide, and relative volume of 1.49 shows ordinary trading. The latest capital event was the August 13, 2026 offering of 3,733,334 shares at USD 1.50 with matching warrants at USD 1.75, so the quote is 73% below the offer, own arithmetic. Cash of USD 5.1 million compares with USD 18.6 million used in operations over six months, USD 3.1 million a month. Adding USD 4.8 million of net offering proceeds gives a 3.2-month runway from June 30, own arithmetic. An at-the-market program allows sales of up to USD 100 million, capped at one-third of public float, so each sale lowers existing holders' ownership. Turnover was USD 148,000, 17.6% of the published USD 840,630 market value, own arithmetic. That value equals only 2.09 million shares; including the offering gives 5.82 million shares and USD 2.34 million, own arithmetic. A 1-for-20 reverse split took effect on July 6. Curis (NASDAQ:CRIS) depends on new financing, and lead drug emavusertib is in early clinical development.

Jaguar Health (NASDAQ:JAGX)

Jaguar declared a special dividend of one Series R convertible preferred share per common share held on October 13, paid October 15. Each preferred share converts into five common shares on November 2, 2026, capped at 19.99% ownership per holder. A holder of one share ends with six, so full adjustment implies an 83% lower per-share price, USD 0.61 on USD 3.65, own arithmetic. The measured 20.48% fall is far smaller, and the price level is not independently confirmed. Volume was 291,280 shares, USD 1.06 million of turnover, 15.0% of the USD 7.1 million market capitalization, own arithmetic. The board called the dividend dilution protection during a review of strategic alternatives and gave no specifics. A 1-for-15 reverse split began trading on September 17, and published EPS of negative 5,482.20 is a per-share figure not independently confirmed. Napo reported preliminary short bowel syndrome results on October 13, but crofelemer is unapproved there, and the microvillus inclusion disease filing is planned for mid-2027. Cash, going concern language and listing status for Jaguar Health (NASDAQ:JAGX) are not disclosed in the filings reviewed.

Where Things Stand

Fractyl fell 48% because investors weighed a modest efficacy gap and a short runway against an endpoint win, while its peers fell on different causes. Own arithmetic ranks decline from the prior close: Fractyl 48%, MDxHealth 40%, Curis 20.83% and Jaguar 20.48%. Turnover as a share of published market capitalization ranks Fractyl 33.5%, Curis 17.6%, Jaguar 15.0% and MDxHealth 1.0%. MDxHealth (NASDAQ:MDXH) has a revenue miss and suspended guidance. Curis (NASDAQ:CRIS) has the shortest computed runway, 3.2 months. Next dated events are the October 20 lead plaintiff deadline for Fractyl Health (NASDAQ:GUTS), the November 2 conversion at Jaguar and the November 12 MDxHealth call. The post-conversion share count at Jaguar Health (NASDAQ:JAGX) is the next disclosure to watch.